The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross‐sectional serosurvey
Medical Journal of Australia · 2024
DOI: 10.5694/mja2.52320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Journal of Australia, 2024. Verfasst von Zoe Baldwin und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT. Hauptthemen laut MEDLINE: Antibodies, Viral, Encephalitis Virus, Japanese, Encephalitis, Japanese. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health, New South Wales Government, New York State Department of Health.
Abstract (Originalsprache)
Objectives
To determine the proportion of people in New South Wales towns at high risk of Japanese encephalitis virus (JEV) infections during the 2022 outbreak; to identify risk factors for JEV infection. Study design Cross‐sectional serosurvey study of the seroprevalence of JEV‐specific antibodies in NSW. Setting, participants Convenience sample of people (all ages) from five regional NSW towns deemed to be at high risk of JEV infections after first outbreak of Japanese encephalitis in southeastern Australia in early 2022 (Balranald, Corowa, Dubbo, Griffith, Temora), 21 June – 22 July 2022. Main outcome measures Proportion of people seropositive for JEV total antibody, assayed by defined epitope‐blocking enzyme‐linked immunosorbent assay; prevalence odds ratios for exposure risk factors and protective behaviours.
Results
Eighty of 917 eligible participants (559 girls or women, 61%; 42 Aboriginal and Torres Strait Islander people, 4.6%; median age, 52 years [IQR, 37–62 years]) were seropositive for JEV‐specific total antibody (8.7%); the median age of seropositive people was 61 years (IQR, 48–70 years). The seropositivity proportion was largest for people aged 65 years or more (30 of 192; weighted proportion, 13.7%) and larger for male than female participants (30 of 358, 10.6% v 50 of 559, 7.5%). Five of 42 samples from Aboriginal and Torres Strait Islander participants were seropositive (12%). We found mixed associations with a range of potential risk factors.
Conclusion
We found evidence for a substantial number of JEV infections in five regional NSW towns during a single arbovirus season in 2022. Public health responses, including effective surveillance, vaccination against JEV, and mosquito management, are critical for controlling outbreaks. Promoting behaviours that reduce exposure to mosquitoes is a core component of prevention, particularly when the vaccine supply is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
- Hunter New England Local Health District, Newcastle, NSW.
- CIDMLS Institute of Clinical Pathology and Medical Research, Sydney, NSW.
- Southern and Murrumbidgee Local Health District, Goulburn, NSW.
- Western New South Wales Local Health District, Dubbo, NSW.
- Sydney School of Public Health, University of Sydney, Sydney, NSW.
ORCID-Profile: Zoe Baldwin, Archana Koirala, Kristine Macartney
Förderung
- Department of Health, New South Wales Government
- New York State Department of Health
Zitieren
APA
Baldwin, Z., Hueston, L., Roberts-Witteveen, A., Stanley, P., Sheel, M., Winkler, N., Koirala, A., Macartney, K., Case, J., Hope, K., & Glasgow, K. M. (2024). The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross‐sectional serosurvey. Medical Journal of Australia. https://doi.org/10.5694/mja2.52320
Vancouver
Baldwin Z, Hueston L, Roberts-Witteveen A, Stanley P, Sheel M, Winkler N, et al. The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross‐sectional serosurvey. Medical Journal of Australia. 2024. doi:10.5694/mja2.52320
BibTeX
@article{Baldwin2024,
author = {Baldwin, Zoe and Hueston, Linda and Roberts-Witteveen, April and Stanley, Priscilla and Sheel, Meru and Winkler, Noni and Koirala, Archana and Macartney, Kristine and Case, Jennifer and Hope, Kirsty and Glasgow, Keira M},
title = {The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross‐sectional serosurvey},
journal = {Medical Journal of Australia},
year = {2024},
doi = {10.5694/mja2.52320}
}
EUVIMED